科研之友
微信
新浪微博
Facebook
分享链接
摘要
Introduction: Anti-TNF- therapy is a novel approach that has transformed the way moderate-to-severe Crohn's disease (CD) is treated and has significantly improved clinical outcomes of patients with enhanced remission induction and maintenance efficacies. As a result, anti-TNF- agents have become the primary cost driver in the treatment of CD, as the frequency of hospitalizations and surgical interventions have been drastically reduced.Areas Covered: In the review, the authors cover current anti-TNF- treatments for CD including efficacy, mechanisms of action, pharmacokinetics and safety. In addition, the authors discuss future anti-TNF- agents currently in the development pipeline including biosimilars, golimumab, oral AVX-470, TNF--kinoid vaccine, and non-biologic HMPL-004.Expert opinion: While new therapeutics are in the pipeline like anti-integrin and anti-interleukin therapeutics, anti-TNF- therapy remains at the forefront of CD treatment due to its long-term efficacy and safety profiles. The next horizon for new anti-TNF- agents is biosimilars, which offer comparable safety and effectiveness to the originator molecules. Biosimilars promise to expand accessibility to anti-TNF- therapy while significantly reducing the cost burden to patients and healthcare systems.
- 出版日期2016-2-1
